Cyclosporine A in addition to standard ART during primary HIV-1 infection: pilot randomized clinical trial

Simple item page
dc.contributor.authorNicolás, David
dc.contributor.authorAmbrosioni, Juan
dc.contributor.authorSued, Omar
dc.contributor.authorBrunet, Mercé
dc.contributor.authorLópez-Diéguez, María
dc.contributor.authorManzardo, Christian
dc.contributor.authorAgüero, Fernando
dc.contributor.authorTuset, Montserrat
dc.contributor.authorPlana, Montserrat
dc.contributor.authorGuardo, Alberto C
dc.contributor.authorMosquera, María Mar
dc.contributor.authorMuñoz-Fernández, M. Ángeles
dc.contributor.authorCaballero, Miguel
dc.contributor.authorMarcos, M. Ángeles
dc.contributor.authorGatell, Jose
dc.contributor.authorde Lazzari, Elisa
dc.contributor.authorGallart, Teresa
dc.contributor.authorMiró, José M
dc.date.accessioned2024-05-23T23:49:11Z
dc.date.available2024-05-23T23:49:11Z
dc.date.issued2016-12-13
dc.descriptionFil: Sued O. Fundación Huésped, Buenos Aires; Argentinaes_ES
dc.description.abstractBackground: Initiating ART during acute/recent HIV-1 infection reduces viral reservoir formation. It has been proposed that, during this phase, the size of the viral reservoir could be further reduced by the association of immunomodulatory therapy with ART. Contradictory results have emerged, however, from two trials evaluating the impact on immune recovery and the viral reservoir of adding cyclosporine A to ART during primary HIV-1 infection. Patients and methods: Twenty patients with acute/recent HIV-1 infection were randomized to receive ART alone (tenofovir, emtricitabine and lopinavir/ritonavir) or associated with 8 weeks of cyclosporine A (0.3–0.6 mg/kg twice daily). The impact on viral load, immune response and integrated and non-integrated DNA viral reservoir at 0, 8 and 36 weeks of treatment was evaluated. Results: The estimated median time from HIV-1 infection to ART onset was 63 days (IQR 53; 79.5) with 90% of patients at Fiebig V stage. No significant differences were observed in viral load decay, CD4 T cell recovery, immune response markers or the evolution of integrated DNA at week 8 (end of cyclosporine A) and week 36 between groups. However, non-integrated DNA significantly increased in the cyclosporine A arm between weeks 0 and 36. Cyclosporine A was well tolerated. Conclusions: Adding cyclosporine A to ART during acute/recent infection did not improve immune recovery. However, unintegrated DNA increased in the cyclosporine A group, suggesting an anti-integration effect, a point warranting further research (ClinicalTrials.gov Identifier: NCT00979706).es_ES
dc.formatapplication/pdfes_ES
dc.identifier.doihttps://doi.org/10.1093/jac/dkw462
dc.identifier.urihttps://repositorio.huesped.org.ar/handle/123456789/1322
dc.languageENGes_ES
dc.provenancePublishedes_ES
dc.relation.ispartofseriesJournal of Antimicrobial Chemotherapy;2017 Mar;72(39);829-36
dc.rightsopenAccesses_ES
dc.subjectImmunityes_ES
dc.subjectDNAes_ES
dc.subjectT-Lymphocyteses_ES
dc.subjectInfectionses_ES
dc.subjectArmes_ES
dc.subjectCyclosporinees_ES
dc.subjectHIV-1es_ES
dc.titleCyclosporine A in addition to standard ART during primary HIV-1 infection: pilot randomized clinical triales_ES
dc.typeArticuloes_ES

Files

Original bundle
Now showing 1 - 1 of 1
Thumbnail Image
Name:
10.1093jacdkw462.pdf
Size:
259.71 KB
Format:
Adobe Portable Document Format
Description:
10.1093/jac/dkw462_eng
Download
License bundle
Now showing 1 - 1 of 1
No Thumbnail Available
Name:
license.txt
Size:
1.71 KB
Format:
Plain Text
Description:
Download

Collections

Articulos científicos